Generic Name:
Acalabrutinib
Project Status:
Complete
Therapeutic Area:
Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL)
Manufacturer:
AstraZeneca Canada Inc.
Brand Name:
Calquence
Project Line:
Reimbursement Review
Project Number:
PC0210-000
NOC Date:
Details
Strength:
100 mg
Tumour Type:
Leukemia
Indications:
Chronic Lymphocytic Leukemia (CLL) (previously untreated)
Funding Request:
With or without obinutuzumab, for the treatment of patients with previously untreated chronic lymphocytic leukemia (CLL) for whom a fludarabine-based regimen is inappropriate.
Review Status:
Complete
Sponsor:
AstraZeneca Canada Inc.
Submission Date:
Submission Deemed Complete:
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Reimburse with clinical criteria and/or conditions
pERC Meeting:
Final Recommendation Issued: